Trump’s tariff comeback: 10–12.5% levies on 60 economies—this week’s trade shock?

The Trump administration is reportedly preparing a replacement for an expiring “universal” tariff framework, with new trade levies potentially set at 10% to 12.5% on goods coming from 60 economies. According to Financial Times reporting cited by Kommersant, the administration is considering introducing the new charges as early as this week, signaling a fast pivot from the prior tariff structure. Separate commentary also frames the move as an attempt to resurrect the broad tariffs Trump announced on “Liberation Day” last year, raising questions about continuity, scope, and enforcement. A third article focuses on whether “generic drug tariffs” could pull manufacturing back to the United States, linking tariff design to industrial policy outcomes. Geopolitically, broad tariff reactivation is a direct instrument of leverage that can reshape bargaining positions with multiple trading partners at once, rather than negotiating bilaterally. The proposed 10%–12.5% band suggests an intention to materially change relative prices, potentially forcing exporters to absorb costs or redirect supply chains. This approach benefits U.S. political objectives—signaling toughness and creating leverage ahead of future trade talks—while increasing friction with countries whose market access depends on current tariff levels. The losers are likely to be import-dependent sectors and consumers facing higher landed costs, while partners may retaliate or accelerate diversification away from U.S.-bound trade. Market and economic implications could be immediate for trade-sensitive equities and for pricing of goods exposed to tariff pass-through. A broad tariff sweep typically pressures industrial inputs, retail margins, and logistics-linked demand, which can weigh on sectors such as consumer discretionary, industrials, and parts of healthcare supply chains if drug-related components are tariffed. The “generic drug tariffs” angle adds a specific risk channel: higher costs for active ingredients, packaging, or finished generics could translate into upward pressure on pharmaceutical pricing and procurement budgets. In FX and rates, tariff-driven inflation expectations can support a higher-for-longer narrative for policy rates, while risk-off sentiment can lift demand for defensive assets. What to watch next is whether the administration formally announces the tariff schedule and the exact product coverage, including how “universal” is defined and whether exemptions or phase-ins are offered. Traders should monitor signals of partner pushback—public statements, retaliatory tariff threats, or accelerated trade negotiations—because these determine whether the shock remains contained or broadens. For the manufacturing question, the key trigger is evidence of reshoring incentives translating into new U.S. capacity for generic drug production, which would likely show up in corporate guidance and supply-chain investment announcements. The near-term escalation/de-escalation timeline hinges on whether implementation begins “this week” as reported, and on whether subsequent guidance clarifies enforcement dates, compliance mechanisms, and any carve-outs for critical inputs.

Geopolitical Implications

• 01

  Multi-country tariff leverage increases bargaining power but raises retaliation risk.

• 02

  Targeting generic drugs signals industrial-policy priorities that can reshape supply chains.

• 03

  Fast implementation timing suggests tariffs are being used as a near-term negotiation tool.

Key Signals

• —Official tariff schedule and HS-code product coverage.
• —Partner retaliation threats or exemption negotiations.
• —Corporate guidance on cost pass-through for imports and generics.
• —Bond yields and inflation breakevens reacting to tariff headlines.